Gemeinschaftskrankenhaus Bonn
Endocrinology
Markus Menzen, MD, PhD Senior Physician, Department of Internal Medicine, Community Hospital Bonn, Germany Markus Menzen, PhD, is a Senior Physician in endocrinology, diabetology and angiology at the Department of Internal Medicine at the Community Hospital Bonn in Germany. He received his degree in medicine from the Rheinische Friedrich-Wilhelm University in Bonn, Germany, and went on to study neuronal opioid receptors for his doctorate. Markus is a member of several prestigious boards in Germany, including the German Society of Internal Medicine and the German Society of Endocrinology. He is also a member of the German Diabetes Society where he has a position on the board for a working group in diabetes and cardiology, was conference president of a working group on diabetic foot, and has a role in the German Diabetes Society’s guidelines commission. Recently, Markus has been involved in recent analyses on the effects of SGLT-2 inhibitors on haematocrit in people with diabetes treated with insulin. His current interests include optimising and implementing personalised treatment for his patients with diabetes, and he has several publications in this field.

Presenter of 4 Presentations

Smart futures: what could the digital health era look like?

Session Type
Industry Symposium
Date
Fri, 29.04.2022
Session Time
10:30 - 12:00
Room
Hall 116
Lecture Time
11:45 - 11:55

Digital diabetes management: a new reality of living with diabetes

Session Type
Industry Symposium
Date
Fri, 29.04.2022
Session Time
10:30 - 12:00
Room
Hall 116
Lecture Time
11:20 - 11:30

Unmet needs in glycaemic control: the role of smart devices

Session Type
Industry Symposium
Date
Fri, 29.04.2022
Session Time
10:30 - 12:00
Room
Hall 116
Lecture Time
10:55 - 11:05

DIABELOOP IN LONG STANDING TYPE 1 DIABETES WITH DEMENTIA

Session Type
Virtual Oral Presentations Session
Date
Fri, 29.04.2022
Session Time
09:00 - 10:00
Room
Virtual Hall 1.1
Lecture Time
09:16 - 09:24

Abstract

Background and Aims

CASE-REPORT

DIABELOOP IN LONG STANDING TYPE 1 DIABETES WITH DEMENTIA

Menzen M1, Ostrowski-Krause M1, Otten F2, Mohr S1

1 Gemeinschaftskrankenhaus Bonn, Department of Endocrinology

2 Gemeinschaftskrankenhaus Bonn, Department of Geriatrics

85 years old woman with type 1 diabetes, diagnosed 1946. Now treated with multiple dose injection of insulin lispro to mealtime 1IU at morning, 0,5 IU at lunch and dinner per 10g carbohydrate and 6 Units of detemir once daily. HbA1c 60 mmol/mol, stimulated c-Peptid: 0,046ng/ml.

Concomitant diseases: Heart failure with preserved ejection fraction, pulmonary arterial hypertension. Frailty with severe sarcopenia (Frailty Share FI 75), incipient dementia (MMST 23/30) with dominant deficits in visuoconstructive skills.

2021 she suffered from two severe hypoglycemia stage III with falls and fracture of os pubis and cranial brain trauma. Both situations caused by unintentional double injection of bolus insulin. Even CGMS with Dexcom G6 supervised by social worker was not able to prevent the rapide drop of blood sugar.

Methods

We decided to switch therapy to automated insulin delivery with AccuChek insight, Dexcom G6 combined with Diabeloop DBLG1 with insulin aspart. No meal annoncement was done. She ate 40g of carbohydrates to each meal.

Results

Tissue glucose in mean was ~180mg/dl with no hypoglycemia and rise after meal up to a maximum of 284 mg/dl for a few minutes with rapid drop to upper range targets. Betahydroxybutrate measured in this situations has been in normal ranges.

Conclusions

This is the first case report of AID use in long standing type 1 diabetes with dementia to our knowledge.

Hide